drugset

drugset / Trial / NCT07008118

A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

NCT07008118 ↗

Phase 1 Recruiting 120 enrolled Incyte Corporation

Non-randomizedSequentialOpen-labelTreatment

Summary

This study is being conducted to evaluate the safety and tolerability of INCA035784 in participants with myeloproliferative neoplasms.

Timeline

Start: 2025-10-01
Primary completion: 2028-03-14
Completion: 2029-12-14

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	INCA035784	Unknown	—	—

Indications